SEPRACOR R-ALBUTEROL PHASE II INTERIM RESULTS WILL BE PRESENTED
This article was originally published in The Tan Sheet
Executive Summary
SEPRACOR R-ALBUTEROL PHASE II INTERIM RESULTS WILL BE PRESENTED during the Nonprescription and Pulmonary-Allergy Drugs Advisory Committees' Nov. 14-15 meeting on the appropriateness of asthma therapies being available over-the-counter. Sepracor's single-isomer version of albuterol may become the "bronchodilator of choice for asthma therapy in both the Rx and OTC markets," the Marlborough, Mass.-based company speculated in a Nov. 9 press release announcing the issuance of a use patent (5,362,755) for the molecule. The Phase II trial of R-albuterol was initiated in Europe in mild asthmatics. Phase II/III trials are projected to begin in 1995.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning